share_log

Canaccord Genuity Maintains Buy on Inari Medical, Raises Price Target to $94

Canaccord Genuity Maintains Buy on Inari Medical, Raises Price Target to $94

Canaccord Genuity维持对Inari Medical的买入,将目标股价提高至94美元
Benzinga Real-time News ·  2022/09/16 07:56

Canaccord Genuity analyst William Plovanic maintains Inari Medical (NASDAQ:NARI) with a Buy and raises the price target from $92 to $94.

Cancord Genuity分析师William Plovanic维持Inari Medical(纳斯达克:NARI)的买入,并将目标价从92美元上调至94美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发